Life Science Daily News

Breaking news & independent expert insights across pharma, biotech & medtech. Built for the life sciences community. Visit

[Life Science Daily News @LifeScienceDN]

Gum disease is common and rarely measured in trials. A guest piece on LSDN argues it can act as a hidden confounder in cardiometabolic and inflammatory studies. https://t.co/ZRgfXP8qAZ #ClinicalTrials #Periodontitis

[Life Science Daily News @LifeScienceDN]

“Is the list of safe foods getting smaller?”

One of seven questions suggested for clinicians screening IBS patients before a restrictive diet, in a piece on a new study of the low FODMAP diet and disordered eating.
https://t.co/uzjG3JjLkt #IBS #FODMAP

[Life Science Daily News @LifeScienceDN]

Trappsol Cyclo missed its primary endpoint in Phase 3 in Niemann-Pick disease type C (p=0.19). Rafael Holdings says it is still on track to file in Q4.

What it points to instead is in our roundup.
https://t.co/QvBj4Zmq8V #ClinicalTrials #RareDisease

[Life Science Daily News @LifeScienceDN]

A GLP-1 follow-up can look fine on the weight chart while the patient is worried about getting their next prescription. A new piece makes the case for treating cost and access as part of care planning. https://t.co/rgmcpb9GEW

[Life Science Daily News @LifeScienceDN]

The FDA has authorised more than 1,500 AI-enabled medical devices, according to the agency. A new piece looks at what that means for the consultation, and who stays accountable once AI is in the room. https://t.co/2FLtPvXYux #AIinHealthcare #HealthTech

[Life Science Daily News @LifeScienceDN]

New Post: I’m a Black Gestational Carrier. How People Calculate My Risk Is Wrong https://t.co/2cgGOJp5GZ

[Life Science Daily News @LifeScienceDN]

In a blind study, non-expert readers trying to spot AI poetry scored 46.6%, below chance, and preferred the machine poems on several measures. Our new Health Tech piece asks who does the checking instead. https://t.co/poN5UcDM7X #GenerativeAI

[Life Science Daily News @LifeScienceDN]

Busy clinics and strong revenue on paper, then someone asks where the cash is. A new contributed piece argues the problem usually began months earlier, a long way from the billing office. https://t.co/H5FEzTXlL2 #RevenueCycle #HealthcareFinance

[Life Science Daily News @LifeScienceDN]

Two drug candidates may bind a complement target similarly yet differ substantially in how well they suppress complement activity. Why one assay rarely tells them apart: https://t.co/scuoc6xQoe #ComplementSystem #DrugDevelopment

[Life Science Daily News @LifeScienceDN]

Demo day and a night shift in the ED are different stress tests for clinical AI. A model can be right enough to look finished while the human loop goes unfinished, argues @HarveyCastroMd. https://t.co/y98oV3hcGX #ClinicalAI #EmergencyMedicine

[Life Science Daily News @LifeScienceDN]

Draft US rules would likely preserve most licensing deals for Chinese drugs, Reuters reported on 18 September, citing sources. Our new tracker lists 27 China out-licensing deals of $1bn+ from 2026 so far. https://t.co/tXEl2IQCcQ #Biotech #China

[Life Science Daily News @LifeScienceDN]

New Post: Improving Oncolytic Virus Development for Cancer Immunotherapy Research https://t.co/CniaOZnPy7

[Life Science Daily News @LifeScienceDN]

The EU gave colour cosmetics until 2035 to remove intentionally added microplastics. Leave-on products get until 2029. A new piece argues those dates leave less room than they look, and that pharma should take note. https://t.co/RYykA2v5S8 #PFAS #REACH

[Life Science Daily News @LifeScienceDN]

Reaching a metastatic tumour is a courier problem before it is a cancer problem. Antibody clearance, the liver and the spleen get to an injected virus first. New piece on systemic delivery: https://t.co/NuHm1Tg1jZ #Oncology #Virotherapy

[Life Science Daily News @LifeScienceDN]

If one exceptional clinician is holding a digital therapeutic pilot together, the organisation has validated the clinician, the piece argues. So what should a pilot be testing? https://t.co/PpRldGHbZ9 #DigitalTherapeutics #DigitalHealth

[Life Science Daily News @LifeScienceDN]

The FDA calls Atebrioz the third approved treatment for fibrodysplasia ossificans progressiva, a rare bone disorder. It's one of four US approvals in our weekly roundup, plus UK regulatory news and two R&D deals. https://t.co/s3ZhFQgSyN #FDA #RareDisease

[Life Science Daily News @LifeScienceDN]

Merck says remigromig met its BRUNELLO endpoint in diabetic macular oedema. The same release flagged more proliferative retinopathy and vitreous haemorrhage than with ranibizumab, and gave no rates. https://t.co/wsufgArePk #DiabeticMacularOedema #Retina

[Life Science Daily News @LifeScienceDN]

A 50-question online consultation is not necessarily safer than a 25-question one. New on LSDN, a pharmacist's case that every question in an online consultation should have a clear purpose. https://t.co/tcGPPu7O06 #OnlinePharmacy #PatientSafety

[Life Science Daily News @LifeScienceDN]

42 to 46% of barzolvolimab patients reached complete response in two Phase 3 urticaria trials, against 9 to 13% on placebo.

Five more readouts in this week's roundup. Two of the six missed. https://t.co/1IwxHbeWdA #ClinicalTrials #Urticaria

[Life Science Daily News @LifeScienceDN]

New Post: Rethinking the Office: The Need for Healthier Buildings https://t.co/8d8YaRIOiC